Q-omics provides the consensus-scored TRAJ16 profile across patient tissues and cancer cell-line models. TRAJ16 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAJ16 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TRAJ16 RNA expression shows 13,232 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where TRAJ16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ16 survival associations across molecular data types. TRAJ16 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ16 RNA expression–survival associations across cancer types. High TRAJ16 expression shows unfavorable associations in LUAD, UVM, LUSC and OV, but favorable associations in HNSC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAJ16 RNA expression.
This table summarizes TRAJ16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ16 shows lower tumor expression in COAD and THCA and higher tumor expression in KIRC, BRCA and HNSC. The KIRC box plot shows higher TRAJ16 RNA expression in tumor versus normal tissue (log2 FC = +0.281, t-test p < 0.001).
This table shows molecular features associated with TRAJ16 in patient tissues and cancer cell lines. In patient samples, TRAJ16 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
